These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
152 related articles for article (PubMed ID: 11772238)
61. Development of an androgen-deprivation induced and androgen suppressed human prostate cancer cell line. Lee SO; Dutt SS; Nadiminty N; Pinder E; Liao H; Gao AC Prostate; 2007 Sep; 67(12):1293-300. PubMed ID: 17626246 [TBL] [Abstract][Full Text] [Related]
62. Androgen annihilation as a new therapeutic paradigm in advanced prostate cancer. Rove KO; Crawford ED Curr Opin Urol; 2013 May; 23(3):208-13. PubMed ID: 23492838 [TBL] [Abstract][Full Text] [Related]
63. Androgen receptors in early and castration resistant prostate cancer: friend or foe? Pelekanou V; Notas G; Stathopoulos EN; Castanas E; Kampa M Hormones (Athens); 2013; 12(2):224-35. PubMed ID: 23933691 [No Abstract] [Full Text] [Related]
65. Androgen-dependent regulation of Her-2/neu in prostate cancer cells. Berger R; Lin DI; Nieto M; Sicinska E; Garraway LA; Adams H; Signoretti S; Hahn WC; Loda M Cancer Res; 2006 Jun; 66(11):5723-8. PubMed ID: 16740710 [TBL] [Abstract][Full Text] [Related]
66. Biologic agents as adjunctive therapy for prostate cancer: a rationale for use with androgen deprivation. Nelson EC; Cambio AJ; Yang JC; Lara PN; Evans CP Nat Clin Pract Urol; 2007 Feb; 4(2):82-94. PubMed ID: 17287869 [TBL] [Abstract][Full Text] [Related]
67. Rat Prostate Tumor Cells Progress in the Bone Microenvironment to a Highly Aggressive Phenotype. Bergström SH; Rudolfsson SH; Bergh A Neoplasia; 2016 Mar; 18(3):152-61. PubMed ID: 26992916 [TBL] [Abstract][Full Text] [Related]
68. In vivo progression of LAPC-9 and LNCaP prostate cancer models to androgen independence is associated with increased expression of insulin-like growth factor I (IGF-I) and IGF-I receptor (IGF-IR). Nickerson T; Chang F; Lorimer D; Smeekens SP; Sawyers CL; Pollak M Cancer Res; 2001 Aug; 61(16):6276-80. PubMed ID: 11507082 [TBL] [Abstract][Full Text] [Related]
69. Longitudinal analysis of androgen deprivation of prostate cancer cells identifies pathways to androgen independence. D'Antonio JM; Ma C; Monzon FA; Pflug BR Prostate; 2008 May; 68(7):698-714. PubMed ID: 18302219 [TBL] [Abstract][Full Text] [Related]
70. Loss of SPDEF and gain of TGFBI activity after androgen deprivation therapy promote EMT and bone metastasis of prostate cancer. Chen WY; Tsai YC; Yeh HL; Suau F; Jiang KC; Shao AN; Huang J; Liu YN Sci Signal; 2017 Aug; 10(492):. PubMed ID: 28811384 [TBL] [Abstract][Full Text] [Related]
76. Management of androgen-independent prostate cancer. Diaz M; Patterson SG Cancer Control; 2004; 11(6):364-73. PubMed ID: 15625524 [TBL] [Abstract][Full Text] [Related]
77. Interactions between cancer cells and bone microenvironment promote bone metastasis in prostate cancer. Zhang X Cancer Commun (Lond); 2019 Nov; 39(1):76. PubMed ID: 31753020 [TBL] [Abstract][Full Text] [Related]
78. Deciphering Evolutionary Dynamics and Lineage Plasticity in Aggressive Prostate Cancer. Kyprianou N; Lucien F Int J Mol Sci; 2021 Oct; 22(21):. PubMed ID: 34769075 [TBL] [Abstract][Full Text] [Related]
79. The anticancer potential of metformin on prostate cancer. Zaidi S; Gandhi J; Joshi G; Smith NL; Khan SA Prostate Cancer Prostatic Dis; 2019 Sep; 22(3):351-361. PubMed ID: 30651580 [TBL] [Abstract][Full Text] [Related]